Atlas Trials

Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

Clinical trial NCT04574856 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04574856
Sponsor
University of Michigan Rogel Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Glioblastoma
Start date
2020-11-04
Primary completion
2026-11-19
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.